Breccia Massimo, Colafigli Gioia, Molica Matteo, Alimena Giuliana
a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.
Expert Opin Drug Saf. 2016;15(4):525-33. doi: 10.1517/14740338.2016.1145654. Epub 2016 Feb 16.
Tyrosine kinase inhibitors (TKIs) drastically changed the outcome of patients affected by chronic myeloid leukemia, allowing long-term improved overall survival and deep molecular responses.
In this review, all the related and "off target" side effects of different TKIs are reported and reviewed including their pathogenesis, and associated predisposing factors are discussed.
Appropriate identification of adverse events and classification according to CTC scale is required during therapy with TKI, considering the impact on the long-term quality of life. Specific evaluation and stratification of comorbidities and cardiovascular risk profile at baseline is suggested in order to better tailor individualized treatment strategy and identify patients who require strict monitoring of risk factors during treatment.
酪氨酸激酶抑制剂（TKIs）极大地改变了慢性髓性白血病患者的治疗结果，使长期总体生存率得到改善，并实现了深度分子反应。
在本综述中，报告并综述了不同TKIs的所有相关和“脱靶”副作用，包括其发病机制，并讨论了相关的易感因素。
在使用TKI治疗期间，需要根据CTC量表对不良事件进行适当识别和分类，同时考虑其对长期生活质量的影响。建议在基线时对合并症和心血管风险状况进行具体评估和分层，以便更好地制定个体化治疗策略，并识别出在治疗期间需要严格监测危险因素的患者。
